Thermo Fisher Scientific, one of the world’s leading producers of laboratory equipment, diagnostics, and bioprocessing services, has entered into an agreement to acquire Clario for up to $9.4 billion, depending on performance milestones. The deal structure includes approximately $8.88 billion in upfront payment, $125 million due in January 2027, and up to $400 million in potential earnouts based on Clario’s future results.
What makes Clario such an attractive acquisition target? Founded in 2021 through the merger of ERT and Bioclinica, Clario provides advanced solutions for managing data in clinical trials. Perhaps most notably, its systems have been used in over 26,000 clinical studies worldwide and contributed to the approval of about 70% of all drugs in the United States. It’s this intersection of medicine, data, and software that Thermo Fisher appears to view as strategically vital — and where it is now investing heavily.
Clario’s recent growth has also been fueled by the digital transformation of clinical research. The COVID-19 pandemic accelerated the adoption of remote patient monitoring, cloud-based data analytics, and the full digitalization of medical documentation. Since then, demand for solutions like Clario’s has continued to rise. Its collaborations with major pharmaceutical players — from Pfizer to AstraZeneca — have further strengthened its market position.
From Thermo Fisher’s perspective, the acquisition represents a strategic expansion of its digital and data service portfolio. The company has been increasing investments in digital health and life sciences services, both of which are becoming critical amid growing competition and tighter regulation in the pharmaceutical industry. Earlier in 2025, Thermo Fisher also acquired parts of Solventum focused on filtration and membrane technologies for biotechnology and drug manufacturing, in a $4.1 billion deal.
Acquiring Clario is expected to significantly enhance Thermo Fisher’s position, enabling it to offer a more comprehensive, end-to-end suite of solutions — from laboratory equipment and analytical services to software supporting clinical trials — all within a single organization, eliminating the need to rely on multiple independent providers.
